Replies to post #5730 on Biotech Values

[DewDiligence]

Re: OXGN

>>Dew I know you have raised this issue about OXGN before but they keep proceeding and now have about 10 phase I and II studies underway. Are you still convinced this is a problem?<<

Hello, dia76ca. Yes, CA4P’s cardiotoxicity remains a major problem in AMD. I don’t think the drug has a chance to make it in AMD unless the company can develop a local formulation, which is something OXGN has been talking about for a long time with nothing concrete to show.

In myopic macular degeneration (MMD), the patients are younger and much less apt to have a heart condition; hence MMD appears to be a better fit for CA4P than AMD.

Clinical success in OXGN’s cancer program may still be achievable, but I lost interest in the company after the mishap in AMD.

>>Have the company ever publically addressed this issue?<<

Not as directly as they should have. However, management did concede at last year’s annual meeting that the AMD program will not be continued unless they can develop a local formulation.

>>Have any of the very competant Scandinavian posters(eg. kokostrollet) ever responded?<<

When I raised this issue almost a year ago, kokostrollet et al said my hypothesis was preposterous and labeled me a basher and short-seller. This is the pattern that has emerged on virtually every message board where I’ve expressed skepticism about a company’s programs and prospects. Regards, Dew

[mskatiescarletohara]

Re:Oxigene----

They have six ongoing trials to my knowledge, all early stage clinical.

Management did address the cardiac toxicity issues in a conference call a couple of years ago, right after or just before BMY pulled out of the CA4P collaboration. They acknowledged it, however, expressed they did not feel it was a major issue. I think someone from Prudential awhile back within the last year asked about those issues again, and management tip-toed around answering the question directly.

Bottom line is CA4P can induce qLT prolongation; patients taking it must be monitored closely, and those suffering from cardiac problems must be excluded from the enrolling. Folks who are elderly, and not in good cardiovascular health should steer clear.

If BP ever partners, they will have to spend millions on proving safety, especially now with more and more scrutiny from consumers, doctors, health agencies, etc...keeping the FDA on their toes.

Kokostrollet will NEVER say anything bad or negative about OXGN.

katie...